People · Operator
Named in public records as an officer, director or promoter · active 2023–2024 · Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Mirador Therapeutics, Inc. | — | Pharma | Series D+ | $413.0M | $4.0B | 2023 |
Scott K. Glenn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Scott K. Glenn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark C. McKenna | 1 | 2 |
| Timothy K. Andrews | 1 | 2 |
| Paul K. Berns | 1 | 2 |
| Kristina K. Burow | 1 | 2 |
| Joseph K. Papa | 1 | 1 |
| David K. Bonita, M.D. | 1 | 1 |
| Vika K. Brough | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.